Two stocks in Healthcare
NEUCA vs Siemens Healthineers: profit, growth, debt and price compared
NEUCA is stronger on 4 of 7 figures: debt, price for its expected profit, dividend and analysts' view. Siemens Healthineers is stronger on 3: profit margin, sales growth and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| NEUCANEU.WA | Siemens HealthineersSHL.DE | |
|---|---|---|
| Net margin | 1.4% | Stronger: 9.4% |
| Revenue growth, past year | +5.50% | Stronger: +7.30% |
| Debt to equity | Stronger: 45.2% | 74.0% |
| Forward P/E | Stronger: 13.2× | 16.3× |
| Dividend yield | Stronger: 2.49% | 2.28% |
| Analysts | Stronger: Strong buy · 5 | Buy · 20 |
| From its 200-day average | −0.2% | Stronger: +8.2% |
Share price over the past year
- NEUCA−10.9%
- Siemens Healthineers+1.8%
24 Nov 202520 Nov 2026
NEUCA or Siemens Healthineers: which is stronger?
- SHL.DE
Which is more profitable?
Siemens Healthineers keeps more of each sale as profit: 9.4% against 1.4%.
- SHL.DE
Which is growing its sales faster?
Siemens Healthineers is growing its sales faster: +7.30% over the past year, against +5.50%.
- NEU.WA
Which has borrowed less?
NEUCA has borrowed less: its debt is 45.2% of what its shareholders own, against 74.0% for Siemens Healthineers.
- NEU.WA
Which costs less for the profit it is expected to make?
NEUCA costs less for the profit it is expected to make: 13.2× its forward earnings, against 16.3×.
- NEU.WA
Which pays more in dividends?
NEUCA pays more back in dividends for what a share costs: 2.49% a year, against 2.28%.
- NEU.WA
Which do analysts rate higher?
Analysts are warmer on NEUCA: Strong buy, against Buy for Siemens Healthineers.
- SHL.DE
Which is in the stronger price trend?
Siemens Healthineers' price is in the stronger trend: 8.2% above its 200-day average, against 0.2% below.
What each company does
NEU.WANEUCA
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland.
SHL.DESiemens Healthineers
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, and internationally.
Reports results on 4 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.